Addition of tucatinib to trastuzumab/pertuzumab after local therapy for isolated intracranial progression in HER2-positive metastatic breast cancer: primary results of the phase II BRIDGET trial

BACKGROUND: Brain metastases are common in advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer, often with stable extracranial disease. Current guidelines for isolated intracranial progression recommend local therapy followed by continuation of the same systemic regimen, given the absence of data supporting a change in therapy. BRIDGET tested whether adding tucatinib, a central nervous system (CNS)-active, HER2-targeted tyrosine kinase inhibitor, to an ongoing HER2-targeted backbone prevents further intracranial progression after isolated CNS relapse. MATERIALS AND METHODS: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib (BRIDGET) is a single-arm, phase II trial (NCT05323955) enrolling patients with metastatic HER2-positive breast cancer experiencing a first or second isolated intracranial event with stable/absent extracranial disease while on trastuzumab/pertuzumab (TP) or ado-trastuzumab emtansine. All new or progressive brain lesions >5 mm underwent stereotactic radiosurgery before enrollment. Tucatinib 300 mg b.i.d. was added continuously to anti-HER2 antibody backbone therapy. The primary endpoint was intracranial progression-free survival (iPFS) per Response Assessment in Neuro-Oncology Brain Metastases. The study was designed to distinguish a 3-month improvement in PFS to >8.0 months versus a historical control median of 5.0 months by one-sample log-rank test (one-sided α = 0.05; 90% power). RESULTS: Of 48 patients, 47 were eligible and assessable (median age 53.5 years; 97.9% female; 93.6% on backbone TP). At a median follow-up of 19.6 months, the study met its primary endpoint: median iPFS was not reached and significantly exceeded the prespecified historical control estimate of 5.0 months (P < 0.0001). 12- and 18-month iPFS estimates were 64% [95% confidence interval (CI) 48-76] and 59% (95% CI 42-73). Extracranial progression was rare (2 patients, 4.3%), and overall survival was exceptional (46 of 47 patients alive). Among patients with isolated CNS relapse as their first and only metastatic event (n = 25), 12-month iPFS was 62%. Grade ≥3 adverse events occurred in 32% (15 of 47). CONCLUSIONS: Addition of tucatinib to ongoing HER2-targeted therapy prolonged intracranial PFS after isolated CNS progression, with excellent survival and a favorable safety profile, supporting its use as an effective strategy for HER2-positive isolated or brain-only relapse. TRIAL REGISTRATION: ClinicalTrials.gov NCT05323955.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-11-13
DOI
https://doi.org/10.1016/j.esmoop.2026.108641
Primary Topic
Brain Metastases and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Addition of tucatinib to trastuzumab/pertuzumab after local therapy for isolated intracranial progression in HER2-positive metastatic breast cancer: primary results of the phase II BRIDGET trial

Amanda E.D. Van Swearingen, Carey K. Anders, Laura Ann Huppert, Rashmi Krishna Murthy et al.
ESMO Open
Brain Metastases and Treatment
article

Addition of tucatinib to trastuzumab/pertuzumab after local therapy for isolated intracranial progression in HER2-positive metastatic breast cancer: primary results of the phase II BRIDGET trial

Amanda E.D. Van Swearingen, Carey K. Anders, Laura Ann Huppert, Rashmi Krishna Murthy, Nusayba Ali Bagegni, Gloria Broadwater, A. Conlin, N.U. Lin, Jamie Douthitt, K. Strickland, Stephanie Masheck, Lisa Wood, S. Beyer, Maura Buckley, Ashley Hughes, Allison Lipps, S.-H. Jung, A. Morikawa, Brian Kostoff, S.L. Sammons
article en

Abstract

BACKGROUND: Brain metastases are common in advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer, often with stable extracranial disease. Current guidelines for isolated intracranial progression recommend local therapy followed by continuation of the same systemic regimen, given the absence of data supporting a change in therapy. BRIDGET tested whether adding tucatinib, a central nervous system (CNS)-active, HER2-targeted tyrosine kinase inhibitor, to an ongoing HER2-targeted backbone prevents further intracranial progression after isolated CNS relapse. MATERIALS AND METHODS: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib (BRIDGET) is a single-arm, phase II trial (NCT05323955) enrolling patients with metastatic HER2-positive breast cancer experiencing a first or second isolated intracranial event with stable/absent extracranial disease while on trastuzumab/pertuzumab (TP) or ado-trastuzumab emtansine. All new or progressive brain lesions >5 mm underwent stereotactic radiosurgery before enrollment. Tucatinib 300 mg b.i.d. was added continuously to anti-HER2 antibody backbone therapy. The primary endpoint was intracranial progression-free survival (iPFS) per Response Assessment in Neuro-Oncology Brain Metastases. The study was designed to distinguish a 3-month improvement in PFS to >8.0 months versus a historical control median of 5.0 months by one-sample log-rank test (one-sided α = 0.05; 90% power). RESULTS: Of 48 patients, 47 were eligible and assessable (median age 53.5 years; 97.9% female; 93.6% on backbone TP). At a median follow-up of 19.6 months, the study met its primary endpoint: median iPFS was not reached and significantly exceeded the prespecified historical control estimate of 5.0 months (P < 0.0001). 12- and 18-month iPFS estimates were 64% [95% confidence interval (CI) 48-76] and 59% (95% CI 42-73). Extracranial progression was rare (2 patients, 4.3%), and overall survival was exceptional (46 of 47 patients alive). Among patients with isolated CNS relapse as their first and only metastatic event (n = 25), 12-month iPFS was 62%. Grade ≥3 adverse events occurred in 32% (15 of 47). CONCLUSIONS: Addition of tucatinib to ongoing HER2-targeted therapy prolonged intracranial PFS after isolated CNS progression, with excellent survival and a favorable safety profile, supporting its use as an effective strategy for HER2-positive isolated or brain-only relapse. TRIAL REGISTRATION: ClinicalTrials.gov NCT05323955.

ESMO OpenVol. 11(12)
University of Maryland, Baltimore (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), Duke University (US), University of California, San Francisco (US), Washington University in St. Louis (US), University of Michigan (US), Providence Portland Medical Center (US), Novant Health (US), The Ohio State University Wexner Medical Center (US), Dana-Farber Cancer Institute (US), Duke Medical Center (US), UCSF Helen Diller Family Comprehensive Cancer Center (US), U-M Rogel Cancer Center (US), University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (US), Duke Cancer Institute (US), Alvin J. Siteman Cancer Center (US)
Pfizer
Good health and well-being
Brain Metastases and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon